Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2

Hypertension

Volumn 48, Issue 1, 2006, Pages 141-148

  Mogi, Masaki ^a   Li, Jian Mei ^a   Iwanami, Jun ^a   Min, Li Juan ^a   Tsukuda, Kana ^a   Iwai, Masaru ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Antihypertensive agents; Central nervous system; Neuroregulators; Receptors angiotensin II; Stroke

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; METHYL METHANESULFONATE SENSITIVE 2; NEUROPROTECTIVE AGENT; PROTEIN; SMALL INTERFERING RNA; UBIQUITIN CONJUGATING ENZYME; UNCLASSIFIED DRUG; VALSARTAN; ANGIOTENSIN II; DRUG DERIVATIVE; MESSENGER RNA; MMS2 PROTEIN, MOUSE; TETRAZOLE DERIVATIVE; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN REGION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FETUS; MALE; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; TRANSCRIPTION INITIATION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANGIOTENSIN II; ANIMALS; BRAIN ISCHEMIA; CELL DIFFERENTIATION; CELLS, CULTURED; COGNITION; MICE; MICE, INBRED C57BL; NEURONS; RECEPTOR, ANGIOTENSIN, TYPE 2; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TETRAZOLES; TRANS-ACTIVATION (GENETICS); UBIQUITIN-CONJUGATING ENZYMES; VALINE;

EID: 33745993277     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000229648.67883.f9     Document Type: Article

References (47)

1. Schiffrin EL. Progress in secondary prevention of stroke with PROGRESS. The perindopril protection against recurrent stroke study. Curr Hypertens Rep. 2002;4:39-40.
2. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
3. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
4. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34:1699-1703.
5. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
6. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, Sakanaka M, Shiuchi T, Horiuchi M. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 2004;110:843-848.
7. Tedesco MA, Ratti G, Mennella S, Manzo G, Grieco M, Rainone AC, Iarussi D, Iacono A. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens. 1999;12:1130-1134.
8. Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol. 1991;261:R209-R216.
9. Wright JW, Harding JW. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Regul Pept. 1995;59:269-295.
10. Zhu YZ, Chimon GN, Zhu YC, Lu Q, Li B, Hu HZ, Yap EH, Lee HS, Wong PT. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. Neuroreport. 2000;11:1191-1194.
11. Gallinat S, Yu M, Dorst A, Unger T, Herdegen T. Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. Brain Res Mol Brain Res. 1998;57:111-122.
12. Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med. 1998;188:661- 670.
13. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182-1191.
14. Reinecke K, Lucius R, Reinecke A, Rickert U, Herdegen T, Unger T. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-κB. FASEB J. 2003;17:2094-2096.
15. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, Blume A, Zimmermann M, Seidel K, Dirnagl U, Unger T. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J. 2005;19:617-619.
16. Gendron L, Laflamme L, Rivard N, Asselin C, Payet MD, Gallo-Payet N. Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol. 1999;13:1615-1626.
17. Cote F, Laflamme L, Payet MD, Gallo-Payet N. Nitric oxide, a new second messenger involved in the action of angiotensin II on neuronal differentiation of NG108-15 cells. Endocr Res. 1998;24:403-407.
18. Cote F, Do TH, Laflamme L, Gallo JM, Gallo-Payet N. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem. 1999;274:31686-31692.
19. Moraes TF, Edwards RA, McKenna S, Pastushok L, Xiao W, Glover JN, Ellison MJ. Crystal structure of the human ubiquitin conjugating enzyme complex, hMms2-hUbc13. Nat Struct Biol. 2001;8:669-673.
20. VanDemark AP, Hofmann RM, Tsui C, Pickart CM, Wolberger C. Molecular insights into polyubiquitin chain assembly: crystal structure of the Mms2/Ubc13 heterodimer. Cell. 2001;105:711-720.
21. Hofmann RM, Pickart CM. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell. 1999;96:645-653.
22. Chopp M, Chan PH, Hsu CY, Cheung ME, Jacobs TP. DNA damage and repair in central nervous system injury: National Institute of Neurological Disorders and Stroke Workshop Summary. Stroke. 1996;27:363-369.
23. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron. 2003;40:427-446.
24. Hofsaess U, Kapfhammer JP. Identification of numerous genes differentially expressed in rat brain during postnatal development by suppression subtractive hybridization and expression analysis of the novel rat gene rMMS2. Brain Res Mol Brain Res. 2003;113:13-27.
25. Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci. 1992;12:4565-4574.
26. Cui TX, Nakagami H, Nahmias C, Shiuchi T, Takeda-Matsubara Y, Li JM, Wu L, Iwai M, Horiuchi M. Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells. Mol Endocrinol. 2002;16:2113-2123.
27. Maeda K, Hata R, Bader M, Walther T, Hossmann KA. Larger anastomoses in angiotensinogen-knockout mice attenuate early metabolic disturbances after middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1999;19:1092-1098.
28. Hata R, Mies G, Wiessner C, Fritze K, Hesselbarth D, Brinker G, Hossmann KA. A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J Cereb Blood Flow Metab. 1998;18:367-375.
29. Hara M, Takayasu M, Watanabe K, Noda A, Takagi T, Suzuki Y, Yoshida J. Protein kinase inhibition by fasudil hydrochloride promotes neurological recovery after spinal cord injury in rats. J Neurosurg. 2000;93:94-101.
30. Li Z, Iwai M, Wu L, Shiuchi T, Jinno T, Cui TX, Horiuchi M. Role of AT2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol. 2003;284:H116-H121.
31. Rodriguez-Pallares J, Quiroz CR, Parga JA, Guerra MJ, Labandeira-Garcia JL. Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur J Neurosci. 2004;20:1489-1498.
32. Li J, Mogi M, Iwanami J, Tsukuda K, Min L, Iwai M, Horiuchi M. AT2 receptor-interacting protein is a pivotal regulator of angiotensin II type 2 receptor-mediated neural differentiation. Stroke. 2006;37:677 (Abstract).
33. Wright JW, Harding JW. The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory. Prog Neurobiol. 2004;72:263-293.
34. Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, Strosberg AD, Nahmias C. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J. 1997;325:449-454.
35. Massa PT, Wu C, Fecenko-Tacka K. Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1-deficient mice. J Neurosci Res. 2004;77:15-25.
36. Nouet S, Amzallag N, Li JM, Louis S, Seitz I, Cui TX, Alleaume AM, Di Benedetto M, Boden C, Masson M, Strosberg AD, Horiuchi M, Couraud PO, Nahmias C. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem. 2004;279:28989-28997.
37. Broomfield S, Chow BL, Xiao W. MMS2, encoding a ubiquitin-conjugating- enzyme-like protein, is a member of the yeast error-free postreplication repair pathway. Proc Natl Acad Sci U S A. 1998;95:5678-5683.
38. Hayashi T, Sakurai M, Itoyama Y, Abe K. Oxidative damage and breakage of DNA in rat brain after transient MCA occlusion. Brain Res. 1999;832:159-163.
39. Garcia JH, Liu KF, Ye ZR, Gutierrez JA Incomplete infarct and delayed neuronal death after transient middle cerebral artery occlusion in rats. Stroke. 1997;28:2303-2310.
40. Reggia JA. Neurocomputational models of the remote effects of focal brain damage. Med Eng Phys. 2004;26:711-722.
41. Sobesky J, Thiel A, Ghaemi M, Hilker RH, Rudolf J, Jacobs AH, Herholz K, Heiss WD. Crossed cerebellar diaschisis in acute human stroke: a PET study of serial changes and response to supratentorial reperfusion. J Cereb Blood Flow Metab. 2005;25:1685-1691.
42. Stenzel-Poore MP, Stevens SL, Simon RP. Genomics of preconditioning. Stroke. 2004;35:2683-2686.
43. Wayner MJ, Armstrong DL, Polan-Curtain JL, Denny JB. Role of angiotensin II and AT1 receptors in hippocampal LTP. Pharmacol Biochem Behav. 1993;45:455-464.
44. Wyss JM, Kadish I, van Groen T. Age-related decline in spatial learning and memory: attenuation by captopril. Clin Exp Hypertens. 2003;25:455-474.
45. Okuyama S, Sakagawa T, Chaki S, Imagawa Y, Ichiki T, Inagami T. Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor. Brain Res. 1999;821:150-159.
46. von Bohlen und Halbach O, Walther T, Bader M, Albrecht D. Genetic deletion of angiotensin AT2 receptor leads to increased cell numbers in different brain structures of mice. Regul Pept. 2001;99:209-216.
47. Vervoort VS, Beachem MA, Edwards PS, Ladd S, Miller KE, de Mollerat X, Clarkson K, DuPont B, Schwartz CE, Stevenson RE, Boyd E, Srivastava AK. AGTR2 mutations in X-linked mental retardation. Science. 2002;296:2401-2403.